Systemic radionuclide therapy in pain palliation

American Journal of Hospice and Palliative Medicine

Volumn 22, Issue 6, 2005, Pages 457-464

  Liepe, Knut ^a   Runge, Roswitha ^a   Kotzerke, Jörg ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bone metastases; Bone pain; Breast cancer; Prostate cancer; Radionuclide therapy

Indexed keywords

EID: 28444454970     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910502200613     Document Type: Article

References (44)

1. McEwan AJ: Palliative therapy with bone seeking radiopharmaceuticals. Cancer Biother Radiopharm. 1998; 13: 413-426.
2. Debes JD, Tindall DJ: The role of androgens and the androgen receptor in prostate cancer. Cancer Lett. 2002; 187: 1-7.
3. Gilligan T, Kantoff PW: Chemotherapy for prostate cancer. Urology. 2002; 60: 94-100.
4. Lewington VJ: Targeted radionuclide therapy for bone metastases. Eur J Nucl Med. 1993; 20: 66-74.
5. Mundy GR: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584-593.
6. Keller ET, Zhang J, Cooper CR, et al.: Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Cancer Metastasis Rev. 2001; 20: 333-349.
7. Scher HI, Yagoda A: Bone metastases: Pathogenesis, treatment, and rationale for use of resorption inhibitors. Am J Med. 1987; 82: 6-28.
8. Maeda H, Koizumi M, Yoshimura K, et al.: Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 1997; 157: 539-543.
9. Demers LM, Costa L, Lipton A: Biochemical markers and skeletal metastases. Cancer. 2000; 88: 2919-2926.
10. Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27: 165-176.
11. Roodman GD: Biology of osteoclast activation in cancer. J Clin Oncol. 2001; 19: 3562-3571.
12. Byrne TN: Spinal cord compression from epidural metastases. N Engl J Med. 1992; 327: 614-619.
13. Nielsen OS, Munro AJ, Tannock IF: Bone metastases: Pathophysiology and management policy. J Clin Oncol. 1991; 9: 509-524.
14. Serafini AN: Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys. 1994; 30: 1187-1194.
15. Enrique O, Zhonyun P, Prma EP, et al.: Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med. 2002; 1: 21-27.
16. Liepe K, Kropp J, Runge R, et al.: Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer. 2003; 89: 625-629.
17. Dafermou AF, Colamussi PF, Giganti MF, et al.: A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med. 2001; 28(7): 788-798.
18. Robinson RG, Preston DF, Schiefelbein MF, et al.: Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA. 1995; 274(5): 420-424.
19. Pecher P: Biological investigation with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. U Cal Publications in Pharmacology. 1942; 2: 117-149.
20. Hosain F, Spencer RP: Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background. Semin Nucl Med. 1992; 22: 11-16.
21. Blake GM, Zivanovic MA, McEwan AJ, et al.: Strontium-89 therapy: Strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma. Br J Radiol. 1987; 60: 253-259.
22. Breen SL, Powe JE, Porter AT: Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992; 33: 1316-1323.
23. Robinson RG, Preston DF, Schiefelbein M, et al.: Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA. 1995; 274: 420-424.
24. Porter AT, Davis LP: Systemic radionuclide therapy of bone metastases with strontium-89. Oncology (Huntingt). 1994; 8: 93-101.
25. Maxon HR 3rd, Thomas SR, Hertzberg VS, et al.: Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med. 1992; 22: 33-40.
26. Maxon HR 3rd, Schroder LE, Hertzberg VS, et al.: Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Results of a double-blind crossover comparison with placebo. J Nucl Med. 1991; 32: 1877-1881.
27. de Klerk JM, Zonnenberg BA, van het Schip AD, et al.: Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med. 1994; 21: 1114-1120.
28. Maxon HR 3rd, Schroder LE, Washburn LC, et al.: Rhenium-188(Sn)HEDP for treatment of osseous metastases. J Nucl Med. 1998; 39: 659-663.
29. Palmedo H, Guhlke S, Bender H, et al.: Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med. 2000; 27: 123-130.
30. Palmedo H, Manka-Waluch A, Albers P, et al.: Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003; 21: 2869-2875.
31. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO, 1979.
32. Lin WY, Lin CP, Yeh SJ, et al.: Rhenium-188 hydroxyethylidene diphosphonate: A new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med. 1997; 24: 590-595.
33. Liepe K, Runge R, Kotzerke J: The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol. 2005; 131: 60-66.
34. Liepe K, Hliscs R, Kropp J, et al.: Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med. 2003; 44: 953-960.
35. Ben-Josef E, Maughan RL, Vasan S, et al.: A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun. 1995; 16: 452-456.
36. Robinson RG, Blake GM, Preston DF, et al.: Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics. 1989; 9: 271-281.
37. Mertens WC, Porter AT, Reid RH, et al.: Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: A preliminary report. J Nucl Med. 1992; 33: 1437-1443.
38. Schmeler K, Bastin K: Strontium-89 for symptomatic metastatic prostate cancer to bone: Recommendations for hospice patients. Hosp J. 1996; 11: 1-10.
39. Kraeber-Bodere F, Campion L, Rousseau C, et al.: Treatment of bone metastases of prostate cancer with strontium-89 chloride: Efficacy in relation to the degree of bone involvement. Eur J Nucl Med. 2000; 27: 1487-1493.
40. Roudier MP, Vesselle H, True LD, et al.: Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis. 2003; 20: 171-180.
41. Pecherstorfer M, Schilling T, Janisch S, et al.: Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med. 1993; 34: 1039-1044.
42. Marcus CS, Saeed S, Mlikotic A, et al.: Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin Nucl Med. 2002; 27: 427-430.
43. Tu SM, Millikan RE, Mengistu B, et al.: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet. 2001; 357: 336-341.
44. Sciuto R, Festa A, Rea S, et al.: Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial. J Nucl Med. 2002; 43: 79-386.